Stable conjugation is fundamental to ADC design and improving therapeutic index. The foundation of Iksuda’s ADCs is its proprietary conjugation chemistry PermaLink^®, which is associated with industry-leading conjugation stability.

PermaLink^® is a cysteine-specific, vinyl pyridine-based chemistry that demonstrates inherent conjugation stability and, unlike many other approaches to conjugation, Iksuda’s PermaLink^® chemistry is not susceptible to drug de-conjugation.

As demonstrated in Preclinical in vivo experiments, PermaLink^® based ADCs are associated with improved tolerability and overall tumour response. The enhanced stability profile of PermaLink^® enables the safer use of ultra-potent toxins which, when conjugated to antibodies that are directed to well-selected targets, results in more efficacious ADCs.